CN117642413A - 化合物及使用了该化合物的标记生物物质 - Google Patents

化合物及使用了该化合物的标记生物物质 Download PDF

Info

Publication number
CN117642413A
CN117642413A CN202280049194.7A CN202280049194A CN117642413A CN 117642413 A CN117642413 A CN 117642413A CN 202280049194 A CN202280049194 A CN 202280049194A CN 117642413 A CN117642413 A CN 117642413A
Authority
CN
China
Prior art keywords
group
compound
substituent
general formula
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280049194.7A
Other languages
English (en)
Chinese (zh)
Inventor
滨田直佳
白兼研史
吉光佑二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN117642413A publication Critical patent/CN117642413A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280049194.7A 2021-08-31 2022-08-30 化合物及使用了该化合物的标记生物物质 Pending CN117642413A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-141996 2021-08-31
JP2021141996 2021-08-31
PCT/JP2022/032639 WO2023032994A1 (ja) 2021-08-31 2022-08-30 化合物及びこれを用いた標識生体物質

Publications (1)

Publication Number Publication Date
CN117642413A true CN117642413A (zh) 2024-03-01

Family

ID=85411242

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280049194.7A Pending CN117642413A (zh) 2021-08-31 2022-08-30 化合物及使用了该化合物的标记生物物质

Country Status (5)

Country Link
US (1) US20240165240A1 (https=)
EP (1) EP4397671A4 (https=)
JP (1) JPWO2023032994A1 (https=)
CN (1) CN117642413A (https=)
WO (1) WO2023032994A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7787670B2 (ja) * 2021-08-31 2025-12-17 富士フイルム株式会社 化合物及びこれを用いた標識生体物質

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5986694A (en) * 1992-12-30 1994-08-15 Baylor College Of Medicine Triplex forming oligonucleotides containing polymeric linkers
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
DE19952956A1 (de) * 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Verbindung von molekularen Substanzen
EP1322710B2 (en) 2000-09-29 2015-02-18 Life Technologies Corporation Modified carbocyanine dyes and their conjugates
EP1281962A1 (en) * 2001-07-30 2003-02-05 Warner-Lambert Company Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and an SH3 domain comprising peptide
WO2008073458A2 (en) 2006-12-11 2008-06-19 Bracco Imaging S.P.A. Fibrin-binding peptides and conjugates thereof
EP2418284A1 (en) * 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
GB201220010D0 (en) 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
WO2015067302A1 (en) * 2013-11-05 2015-05-14 Ecole Polytechnique Federale De Lausanne (Epfl) Sensor molecules and uses thereof
KR101538268B1 (ko) 2014-03-06 2015-07-23 연세대학교 산학협력단 바이오마커 특이적 양친성 나노입자
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
EP3259365B1 (en) * 2015-02-16 2020-04-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Sensors, methods and kits for detecting nicotinamide adenine dinucleotides
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3507603B1 (en) * 2016-09-01 2024-03-06 Life Technologies Corporation Compositions and methods for enhanced fluorescence
CA3057419A1 (en) 2017-03-21 2018-09-27 Fujifilm Corporation Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound
JP2019172826A (ja) 2018-03-28 2019-10-10 富士フイルム株式会社 蛍光性化合物及びこれを用いた蛍光標識生体物質
WO2019230963A1 (ja) 2018-06-01 2019-12-05 富士フイルム株式会社 蛍光性化合物及びこれを用いた蛍光標識生体物質
JP7628073B2 (ja) 2019-02-28 2025-02-07 富士フイルム株式会社 ペプチド化合物の製造方法、保護基形成用試薬、及び、芳香族複素環化合物
JP7344982B2 (ja) 2019-11-21 2023-09-14 富士フイルム株式会社 化合物及びこれを用いた蛍光標識生体物質
JP7394663B2 (ja) 2020-03-10 2023-12-08 グローリー株式会社 遊技情報閲覧システム
WO2022040213A1 (en) * 2020-08-18 2022-02-24 Ultima Genomics, Inc. Reagents for labeling biomolecules

Also Published As

Publication number Publication date
EP4397671A4 (en) 2025-02-19
WO2023032994A1 (ja) 2023-03-09
EP4397671A1 (en) 2024-07-10
JPWO2023032994A1 (https=) 2023-03-09
US20240165240A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
JP7550076B2 (ja) 蛍光色素及びこれを用いた標識生体物質
JP7344982B2 (ja) 化合物及びこれを用いた蛍光標識生体物質
CN116134044B (zh) 化合物及使用了该化合物的标记生物物质
JP7359869B2 (ja) 化合物及びこれを用いた蛍光標識生体物質
US20240173437A1 (en) Compound and labeled biological substance using the same
CN117642413A (zh) 化合物及使用了该化合物的标记生物物质
US20250314658A1 (en) Fluorescence intensity enhancer, fluorescence intensity enhancing method of fluorescently labeled target biological substance, and kit for fluorescence detection
JP7787670B2 (ja) 化合物及びこれを用いた標識生体物質
US12559476B2 (en) Compound and labeled biological substance using the same
US20240182383A1 (en) Compound and labeled biological substance using the same
CN117642412A (zh) 化合物及使用了该化合物的标记生物物质
CN120752249A (zh) 化合物及使用了该化合物的标记生物物质
CN120752250A (zh) 化合物及使用了该化合物的标记生物物质
CN117642414A (zh) 化合物及使用了该化合物的标记生物物质
CN117460789B (zh) 化合物及使用了该化合物的标记生物物质
CN117460790B (zh) 荧光性化合物及使用了该荧光性化合物的荧光标记生物物质
WO2024181456A1 (ja) 化合物及びこれを用いた標識生体物質
WO2025197851A1 (ja) 蛍光性化合物
JP2023059377A (ja) 蛍光性化合物及びこれを用いた蛍光標識生体物質

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination